Observational study of the first-line chemotherapy including cetuximab in patients with metastatic colorectal cancer: CORAL trial.
Kei Muro
Honoraria - Bristol-Myers Squibb; Merck Serono
Michio Itabashi
Honoraria - Bristol-Myers Squibb; Merck Serono
Hiroki Hashida
Honoraria - Merck Serono
Toshiki Masuishi
Honoraria - Bristol-Myers Squibb
Masanori Kotake
Honoraria - Merck KGaA
Tadamichi Denda
Honoraria - Bristol-Myers Squibb; Merck Serono
Yasuo Ohashi
No relevant relationships to disclose
Kenichi Sugihara
Honoraria - Bristol-Myers Squibb; Merck Serono